Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Description

The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and reachable workspace, as well as optional muscle biopsy and wearable device (US participants only).

Conditions

FSHD

Study Overview

Study Details

Study overview

The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and reachable workspace, as well as optional muscle biopsy and wearable device (US participants only).

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Condition
FSHD
Intervention / Treatment

-

Contacts and Locations

Los Angeles

David Geffen School of Medicine at UCLA, Los Angeles, California, United States, 90095

Stanford

Neuromuscular Disorders Program at Stanford University School of Medicine, Stanford, California, United States, 94306

Aurora

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, 80045

Gainesville

Univeristy of Florida Gainesville, Gainesville, Florida, United States, 32608

Iowa City

University of Iowa, Iowa City, Iowa, United States, 52242

Kansas City

Univeristy of Kansas Medical Center, Kansas City, Kansas, United States, 66160

Baltimore

Kennedy Krieger Institute, Baltimore, Maryland, United States, 21205

Rochester

University of Rochester Medical Center, Rochester, New York, United States, 14642

Columbus

The Ohio State University Medical Center, Columbus, Ohio, United States, 43221

Austin

Austin Neuromuscular Center, Austin, Texas, United States, 78759

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Genetically confirmed FSHD (types 1 or 2) or clinical diagnosis of FSHD with characteristic findings on exam and an affected parent or offspring.
  • * Unwilling or unable to provide informed consent.
  • * Any other medical condition which in the opinion of the investigator would interfere with study participation.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Kansas Medical Center,

Jeffrey Statland, MD, PRINCIPAL_INVESTIGATOR, University of Kansas Medical Center

Rabi Tawil, MD, PRINCIPAL_INVESTIGATOR, University of Rochester

Study Record Dates

2028-01